Brief: Oragenics Reports Preliminary Data For Intranasal COVID-19 Vaccine Candidate
24/08/2022 12:07
Aug 24 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ANNOUNCES FAVORABLE PRELIMINARY TOXICOLOGY DATA
FOR
INTRANASAL COVID-19 VACCINE CANDIDATE
* ORAGENICS INC - N T-COV2-1 PRELIMINARY DATA SUPPORTS
REGULATORY
FILINGS FOR PHASE 1 STUDIES
* ORAGENICS INC - INTRANASAL ADMINISTRATION ELICITS IMMUNE
RESPONSES
* ORAGENICS INC - EXPECT TO INITIATE OUR PHASE 1 CLINICAL
STUDY BY
EARLY 2023
Source text for Eikon: ID:nBw2WxWXPa
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing